MacNeill Briain D, Hayase Motoya, Hajjar Roger J
Cardiovascular Research Center, Massachusetts General Hospital - East, Building 149, 149 13th Street, Charlestown, MA 02129-2000, USA.
Curr Atheroscler Rep. 2003 May;5(3):178-85. doi: 10.1007/s11883-003-0021-2.
Congestive heart failure represents an enormous clinical problem demanding effective therapeutic approaches. The varied etiologies of heart failure include abnormalities of ion handling, cellular signaling, neurohormonal control, and apoptosis, all of which are potentially amenable to genetic manipulation. Gene therapy holds the promise of retarding the progression, preventing, and perhaps reversing heart failure. Advances in our knowledge of possible targets, vectors, and delivery techniques have revolutionized this field in recent years, bringing us close to clinical application.
充血性心力衰竭是一个巨大的临床问题，需要有效的治疗方法。心力衰竭的病因多种多样，包括离子处理、细胞信号传导、神经激素控制和细胞凋亡异常，所有这些都可能通过基因操作来解决。基因治疗有望延缓心力衰竭的进展、预防甚至逆转心力衰竭。近年来，我们对可能的靶点、载体和递送技术的认识取得了进展，彻底改变了这一领域，使我们接近临床应用。
